Marker Therapeutics (MRKR)

• Market cap: $13.3M
• 1 day: 5.08%
• 5 days: -21.52%
• 1 month: -27.91%
• 3 months: -69.98%
• 6 months: -56.94%
• Year to date: -61.01%
• 1 year: -72.26%
• 5 years: -92.44%
• 10 years: -97.73%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

Employees: 8

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

772% more capital invested

Capital invested by funds: $5.67M [Q3] → $49.5M (+$43.8M) [Q4]

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

19.15% more ownership

Funds ownership: 22.54% [Q3] → 41.7% (+19.15%) [Q4]

18% more funds holding

Funds holding: 28 [Q3] → 33 (+5) [Q4]

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $8 545% upside
• Avg. target: $8 545% upside
• High target: $8 545% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Canaccord Genuity John Newman 31% 1-year accuracy 9 / 29 met price target

545% upside $8

Buy Initiated

5 Mar 2025